期刊文献+

多西他赛联合阿霉素治疗晚期乳腺癌30例疗效观察 被引量:2

下载PDF
导出
摘要 目的观察多西他赛联合阿霉素对晚期乳腺癌化疗的临床疗效及毒副作用,并对安全性进行评估。方法用多西他赛联合阿霉素治疗晚期乳腺癌30例,用WHO实体瘤近期客观疗效标准及抗肿瘤药急性及亚急性毒性反应分度标准评价疗效及毒性。结果在30例患者中,3例达到完全缓解,12例部分缓解,8例病情稳定,7例出现进展,其中有效率达50%,临床获益率达76.6%。毒副反应以胃肠道反应和骨髓抑制为主,大多为Ⅰ-Ⅲ级。结论多西他赛联合阿霉素对晚期乳腺癌化疗有较好的疗效和耐受性,可作为晚期乳腺癌的治疗方法。
出处 《海南医学》 CAS 2010年第18期36-37,共2页 Hainan Medical Journal
  • 相关文献

参考文献3

二级参考文献27

  • 1徐兵河,赵龙妹,袁芃,储大同.多西紫杉醇联合卡培他滨治疗蒽环类药物耐药性晚期乳腺癌的初步临床结果[J].癌症进展,2004,2(1):18-20. 被引量:24
  • 2徐兵河,李维廉,邸立军.诺维本联合顺铂治疗晚期乳腺癌的多中心临床研究[J].中国肿瘤临床,2004,31(23):1340-1342. 被引量:27
  • 3徐兵河,赵龙妹,王佳玉,袁芃.泰索帝联合顺铂治疗31例蒽环类耐药性晚期乳腺癌疗效分析[J].中华肿瘤杂志,2006,28(6):471-473. 被引量:46
  • 4Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs, 1992, 3:121-124.
  • 5Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol, 1992, 30:444-450.
  • 6Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs, 2000, 59:621-651.
  • 7Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase Ⅱ and phase Ⅲ trials. Clin Breast Cancer, 2000,1 : 32-40.
  • 8Fulton B, Spencer CM. Docetaxel : a review of its pharmaeodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs, 1996, 51 : 1075-1092.
  • 9Kruijtzer CMF, Verweij J, Schellens JH, et al. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands. Anticancer Drugs, 2000, 11:249-255.
  • 10Brodowicz T, Koestler WJ, Tomek S, et al. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer. Anticancer Drugs, 2000, 11:149-153.

共引文献150

同被引文献20

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部